MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured a multi-million dollar funding package led by Oberland Capital to support the commercialization of two gene therapies.
- Intelligence Anchor: MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
- Core Takeaway: MeiraGTx has secured a multi-million dollar funding package led by Oberland Capital to support the commercialization of two gene therapies.
- Signal Velocity: 3 score across 5 independent media sources and 5 indexed articles.
- Forecast Model: Story predicted to decelerate within 24h.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
MeiraGTx has reached a financing agreement involving royalty financing and equity to secure capital. The funding package is intended to support the company’s efforts to bring two gene therapies to market and includes the retirement of existing debt held by Perceptive. Coverage from outlets including Fierce Biotech, TradingView, and Simply Wall St notes that the deal involves up to $375 million in royalty financing plus an additional $10 million in equity.
Investing.com reports that H.C. Wainwright has reiterated its stock rating for the company following the announcement. Upcoming milestones for the company include a BLA filing scheduled for the first half of 2027.
Coverage also points to the Bota-Vec acquisition and upcoming AAV2-hAQP1 data as catalysts to track, though specific details on the commercialization timeline for these assets beyond the filing window remain to be seen.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 132d ago.
The reporting (5)
- MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt TradingView · 134d ago
- Exclusive BAC Article: MeiraGTx; AAV2-hAQP1 Q2 207 Data Xerostomia, BLA Filing 1st Half 2027, Bota-Vec Acquisition, Oberland Capital Cash Infusion, And Catalysts (NASDAQ:MGTX) Seeking Alpha · 134d ago
- MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways simplywall.st · 134d ago
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal Investing.com · 134d ago
- MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Fierce Biotech · 134d ago
The obvious questions
How much funding did MeiraGTx secure?
Reports vary on the total valuation of the financing, with figures cited ranging from $400 million to $425 million.
What is the primary purpose of this capital?
The funding is intended to support the commercialization of two gene therapies and to retire debt held by Perceptive.
When is the next BLA filing expected?
The BLA filing is currently targeted for the first half of 2027.
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
Related trends
Introducing Fierce Biotech's 2026 Fierce 15
Fierce Biotech’s 2026 ‘Fierce 15’ spotlights a new wave of bold, capital‑rich private biotechs racing toward breakthrough medicines.
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
Argenx to Buy Forte Biosciences for $2.2 Billion
A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals stock reaches five-year highs following successful Phase 3 trial results, while shares of competitor Ionis decline.